Heron Therapeutics (HRTX) Other Operating Expenses (2012 - 2026)

Heron Therapeutics has reported Other Operating Expenses for 14 years, with the latest figure at $14.3 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses rose 16.22% year-over-year to $14.3 million; the trailing twelve-month figure through Mar 2026 stood at $51.1 million (up 6.47% YoY), and the FY2025 full-year result was $49.1 million, up 4.2% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $14.3 million, up from $12.2 million in the prior quarter.
• The five-year high for Other Operating Expenses was $39.1 million in Q2 2022, with the low at $11.0 million in Q3 2024.
• Historically, Other Operating Expenses has averaged $16.9 million across 5 years, with a median of $13.0 million in 2023.
• The largest YoY upside for Other Operating Expenses was 42.28% in 2022 against a maximum downside of 49.83% in 2022.
• Heron Therapeutics' Other Operating Expenses stood at $17.8 million in 2022, then sank by 30.64% to $12.3 million in 2023, then retreated by 10.31% to $11.1 million in 2024, then gained by 10.64% to $12.2 million in 2025, then climbed by 16.96% to $14.3 million in 2026.
• The last three Other Operating Expenses figures came in at $14.3 million (Q1 2026), $12.2 million (Q4 2025), and $12.9 million (Q3 2025), per Business Quant data.